Androgen receptor： structure, role in prostate cancer and drug discovery  

作　　者：MH Eileen TAN Jun LI H Eric XU Karsten MELCHER Eu-leong YONG 

机构地区：[1]Department of Obstetrics & Gynecology, National University Hospital, Yong Loo Lin School of Medicine, National University of Singapore, Singapore [2]Laboratory of Structural Sciences, Center for Structural Biology and Drug Discovery, Van Andel Research Institute, Grand Rapids, M149503, USA [3]VARI/SIMM Center, CAS-Key Laboratory of Receptor Research, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai 201203, China

出　　处：《Acta Pharmacologica Sinica》2015年第1期3-23,共21页中国药理学报（英文版）

摘　　要：Androgens and androgen receptors （AR） play a pivotal role in expression of the male phenotype. Several diseases, such as androgen insensitivity syndrome （AIS） and prostate cancer, are associated with alterations in AR functions. Indeed, androgen blockade by drugs that prevent the production of androgens and/or block the action of the AR inhibits prostate cancer growth. However, resistance to these drugs often occurs after 2-3 years as the patients develop castration-resistant prostate cancer （CRPC）. In CRPC, a functional AR remains a key regulator. Early studies focused on the functional domains of the AR and its crucial role in the pathology. The elucidation of the structures of the AR DNA binding domain （DBD） and ligand binding domain （LBD） provides a new framework for understanding the functions of this receptor and leads to the development of rational drug design for the treatment of prostate cancer. An overview of androgen receptor structure and activity, its actions in prostate cancer, and how structural information and high-throughput screening have been or can be used for drug discovery are provided herein.

关 键 词：ANDROGEN ANDROGEN RECEPTOR PROSTATE cancer nuclear RECEPTOR DRUG discovery rational DRUG design structural biology CASTRATION resistance ANTIANDROGEN 

分 类 号：R[医药卫生]